Last reviewed · How we verify
Intravenous Dexmedetomidine infusion
At a glance
| Generic name | Intravenous Dexmedetomidine infusion |
|---|---|
| Also known as | Group D |
| Sponsor | Shaheed Mohtarma Benazir Bhutto Institue of Trauma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- The Effects of Dexmedetomidine on Postoperative Cognitive Function in Open Heart Surgery (NA)
- Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery (PHASE4)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia (NA)
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
- Perioperative Multimodal Analgesia for Supratentorial Craniotomy (NA)
- Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: